Risks and Protective Factors of the Prodromal Stage of Psychosis: A Literature Review

Aldanah Althwanay 1, Nada A. AlZamil 2, Omar Y. Almukhadhib 3, Shahd Alkhunaizi 4, Reem Althwanay 5

1. Internal Medicine, Imam Abdulrahman Bin Faisal University, Khobar, SAU 2. Psychiatry, Imam Abdulrahman Bin Faisal University, Dammam, SAU 3. Medicine, Imam Abdulrahman Bin Faisal University, Dammam, SAU 4. Emergency Medicine, King Fahd Hospital of the University, Dammam, SAU 5. Internal Medicine, Imam Abdulrahman Bin Faisal University, Dammam, SAU

Corresponding author: Aldanah Althwanay, dana_althwanay@hotmail.com

Abstract

Psychosis is a syndrome characterized by features of reality distortion such as delusions and hallucinations. It may occur as a primary mental disorder or secondary to a medical or neurological illness or substance abuse. Several genetic, environmental, and protective risk factors have been identified and require further study. Neurobiological damage at the onset of schizophrenia is the most active and destructive. Therefore, it is important to detect the prodromal phase of psychosis so that interventions can be started early and the onset of psychosis delayed. Herein, we review the relevant epidemiological data on psychosis, particularly in Saudi Arabia. In addition, the risk and protective factors of psychosis will be discussed.

Recent findings have shown that psychosis development is affected by genetic and environmental factors. Psychotic disorders are considered a cause of disability and are, therefore, a substantial economic burden. Consequently, it is important to try and detect the psychosis in its prodromal stage, where intervention may slow its progression and improve general wellbeing. Several tools have been identified to screen for the prodrome of psychosis, one of which is the prodromal questionnaire-brief version. This has been shown to be a promising tool that can be self-administered by the patient in contrast to long interview-based tools, which are time-consuming and require a physician to perform. Despite the limited evidence in the literature, there have been significant improvements in the outcomes of patients with psychosis when treated in the prodromal period.

In summary, this article provides psychiatrists and researchers with an overview of psychosis, its risk factors, the prodromal stage of psychosis, tools to detect the prodromal phase, and potential treatments during this phase.

Introduction And Background

Psychotic disorders are characterized by a disconnection from reality. Psychosis by itself is a syndrome rather than an illness, and it is defined as “the experience of loss of contact with reality that is not part of the person’s cultural or religious beliefs.” Psychoysis is a sign of mental
illnesses that is a diagnosis of exclusion after ruling out secondary causes, such as substance abuse (marijuana) and other illnesses, which might lead to psychosis such as stroke, some types of epilepsy, and brain tumors. Schizophrenia is the most common diagnosis when psychosis has occurred; it has three categories of symptoms: positive, which encompasses psychosis as the main feature, negative, and cognitive [1-5].

Psychotic disorders are associated with significant morbidity and disability, and they are perceived as an evolving brain pathology. Due to brain functional plasticity and adaptation, it is hoped that the early detection of psychosis may prevent disease progression [4]. Thereby, several tools were created to detect the prodromal stage of psychosis, which is defined as preliminary signs and symptoms that do not fulfill the characteristic criteria of the disease [5].

As a complex multifactorial disease, the risk factors can be partitioned into several domains, such as familial, environmental, and psychological [6]. This complex interplay provides an insight into the role of a positive environment and support system in protecting genetically susceptible individuals [7].

Herein, we review the updates of the relevant topic epidemiological data on psychosis, particularly in Saudi Arabia, and discuss the risks and protective factors of psychosis. Although this topic has been discussed extensively in several separate books and articles, each had discussed it by focusing on limited aspects and areas. Hence, we intended to review the available resources, collect all the ideas and theories, and summarize them in our review, providing wider coverage of the topic. It is hoped that this will help in the early detection and treatment of psychosis during the prodromal stage.

**Review**

**Definition of the prodromal stage of psychosis**

The prodromal stage of schizophrenia was first conceptualized in 1911 by Bleuler and was defined as the preliminary signs and symptoms of an illness that does not fulfill the characteristic criteria of the disease [5]. It was defined by Loebel et al. as the time interval from the onset of unusual behavioral symptoms to the onset of psychotic symptoms [8].

The prodromal stage of psychosis can be detected at an early stage through the regular follow-up of high-risk patients to prevent or delay the onset of psychotic disorders. Early management of psychosis leads to better function preservation and, therefore, better long-term outcomes [8-9].

There are three subtypes of prodromal symptoms: brief intermittent psychotic syndrome (BIPS), attenuated positive symptom syndrome (APSS), and genetic risk and deterioration syndrome (GRDS) [9].

Among the general population, psychotic-like symptoms may be experienced by 20% of adults who do not fulfill the criteria for psychotic disorders [10]. Furthermore, according to Cannon et al., 16%-55% of individuals who were diagnosed with ultra-high-risk (UHR) syndrome had developed a psychotic disorder, on average, two to two and half years after recognition [11].

**Tools for the detection of prodromal psychosis**

Many studies have attempted to identify the early signs of psychotic disorders and mood disorders, as early detection and management may improve symptoms, decrease the rate of deterioration and relapses, and improve quality of life overall [1].
Several tools quantitatively assess and rate the severity of prodromal symptoms of psychosis, including Bonn scale for the assessment of basic symptoms (BSABS; Gross et al., 1987), the structured interview for prodromal symptoms (SIPS), the scale of prodromal symptoms (SOPS; McGlashan, 1996), the multidimensional assessment of psychotic prodrome (Yung and McGorry, 1996), and the comprehensive assessment of ARMS (CAARMS; Yung et al., 2005) [12-16].

In 2011, Lowey et al. created the prodromal questionnaire - brief version” (PQ-B), which consists of 21 questions to quantitatively assess the level of prodromal psychosis in an ultra-high risk group (UHR). This was accompanied by a structured interview for prodromal syndromes (SIPS). The PQ-B was found to have a statically significant correlation with SIPS ($P<.0001$). Furthermore, the difference in the total scores between the case and control groups was statistically significant [14]. This is a new promising tool in the field that relies on self-reported symptoms instead of individualized interviews, as in the previously mentioned tools. However, only a few studies have used it as their primary tool to assess prodromal psychosis, none of which were conducted in Saudi Arabia.

Xu et al. performed a pilot study among Chinese help-seeking individuals, assessing the psychometric properties of the PQ-B. In their study, the total PQ-B scores were significantly lower in the non-psychotic group than in the prodromal and psychotic groups, with $p$-values of $<0.001$ and $<0.001$, respectively. After a two-year follow-up, 23.9% of the prodromal group had psychosis [9].

**Effects of early treatment during the prodromal stage of psychosis**

The concept of early intervention in patients with a prodromal risk for psychosis was not introduced until the 1990s. Before that, no one had considered using antipsychotics for prodromal psychosis for several reasons. First, antipsychotics were known only to treat positive symptoms of schizophrenia, and it was not thought that their early use would delay or reduce relapses of the disease. Second, antipsychotics have many undesired side effects. Third, the prodromal symptoms of psychosis were not well-identified to a level that could be used for deciding when to start treatment. Fourth, the diagnosis of psychotic disorders is by exclusion. As such, its diagnosis is delayed, as other causes need to be ruled out first, and this needs to be carefully done to avoid any unnecessary stigma of such diseases [17].

There are a variety of non-specific signs and symptoms that may precede a first psychotic episode and have no specific biological markers. This means that starting treatment, even with insufficient evidence, may be an option [18].

Two clinical trials have provided evidence for early intervention in prodromal psychosis. The first was by Fallon (in 1992), who used home-based stress management techniques to identify high-risk individuals for psychosis by their primary health care physician. The therapy prevented psychosis and caused a reduction in the incidence of schizophrenia among the sample. This study had limited significance due to the small sample size [19]. The second trial was by McGorry et al. in 2002, which compared two treatments approaches among two groups who they have identified as UHR individuals: (1) the on need-based intervention (NBI), consisting of supportive psychotherapy and the possible use of antidepressants if indicated, and (2) the specific therapy intervention (SPI), consisting of low dose risperidone and cognitive behavioral therapy (CBT). The initial follow-up results after six months showed a significant difference between the two treatment groups favoring the SPI in terms of progression to psychosis. After the first six months, both groups were following NBI only; hence, the second follow-up in 12 months did not show any significant differences between both groups in terms of progression to psychosis. However, when the survival analysis is extended, taking into
account levels of antipsychotic drug adherence, a significant difference is maintained between the fully adherent SPI group and the NBI group throughout follow-up. The number needed to treat for the end of treatment was 4 at the 95% confidence interval. This means that four patients would need to be treated to prevent one from progressing to psychosis over a six-month period, indicating that the intervention is relatively potent [20]. However, a most recently published article disagrees, as the administration of antipsychotics to UHR patients is potentially harmful, with no preventive benefits [21].

Nevertheless, Addington et al. suggested that CBT is the promising therapy for the prodromal stage of psychosis where the symptoms are minimal. On the other hand, antipsychotics seem to be beneficial in the later stages of the prodrome, where patients are on the edge to fully convert to psychosis [22].

These controversial results on whether to use antipsychotics in the prodromal stage or not mandate further trials to reach a fair conclusion.

Epidemiology and demographics of mental health and psychotic disorders globally and in Saudi Arabia

The World Health Organization (WHO) estimated that one in four people worldwide has a mental illness. Mental illnesses account for 25% of all disabilities in more developed countries. Moreover, the WHO considers mental illnesses as the leading cause of disability, and they are, therefore, a considerable economic burden [23]. It has also been found that, generally, mental health disorders do not occur on their own and are associated with other psychiatric disorders [24].

The incidence of first-episode psychosis varies widely between different locations but was found to be 42.6/100,000 person-years and 34/100,000 person-years globally. The risk decreases with age, and incidence rates were highest for males and females below 20 years old. There was increased risk among males and certain ethnic groups. Black and mixed ethnicities had an elevated risk and Asians a decreased risk when compared to a white British group. The risk was also increased for people with low socioeconomic status and in more urban and deprived neighborhoods [25-26].

According to the WHO, schizophrenia affects more than 23-million people worldwide, with a prevalence of 1% worldwide [27-28]. Despite the few publications about the prevalence of mental health issues in Saudi Arabia, in 2008, the Saudi Arabian Ministry of Health reported that 22.4% of mental health outpatients were diagnosed with schizophrenia or schizotypal personality and delusional disorders [29].

The median duration of untreated psychosis (DUP) in Saudi Arabia is 1.41 years. It usually takes longer for patients to seek help from psychiatric services in Saudi Arabia than it does in Western countries. This suggests that the duration of untreated psychosis is influenced by both demographic factors and pathways to care [30].

Risk factors for psychosis

According to the WHO, a risk factor is any attribute, characteristic, or exposure that increases the likelihood of developing a disease or injury by an individual. Therefore, a risk factor for psychosis should increase the likelihood of developing psychosis [31]. The risk factors of psychosis can be partitioned into several domains such as familial, environmental, and psychological [6]. For complex multifactorial disease, it seems likely that the co-exposure of two risk factors will have a greater than an additive relationship to disease risk [32].
There is a strong genetic association with psychosis. Genome-wide association studies (GWAS) revealed that several single nucleotide polymorphisms (SNPs) within the ZNF804A gene were strongly associated with schizophrenia. A relatively specific association between a common variation in GABA receptor genes and the occurrence of rare copy number variants (CNVs) has been shown to be increased in schizophrenic patients as compared with controls [35]. Establishing such genetic associations with psychosis is vital as those high-risk SNPs may be used as biomarkers for screening UHR individuals and identifying them earlier.

Studies have shown that the offsprings of a parent with psychosis are likely to be exposed to elements of the family environment that have been implicated in the development of psychotic disorders, e.g., maladaptive parental communication and practices in early childhood. As such, heritability likely influences the development of psychosis by way of gene-environment interactions, rather than through genetics alone. There is evidence that disrupted parenting through separation or death increases the risk of psychosis independently of other risk factors. A meta-analysis by Bailey et al. suggested that different aspects of childhood traumas such as sexual abuse, physical abuse, emotional abuse, and neglect have significantly impacted the development of positive psychotic symptoms such as hallucinations and delusions as well as negative symptoms [6,54].

Unfortunately, there is limited early developmental data on factors such as obesity, diet, and physical inactivity in individuals who later develop psychosis. Some research has suggested that patients with psychosis, on average, have a history of delayed motor development in childhood and adolescence as well as delayed neurological and cognitive development. Physical activity levels were found to be lower among children and adolescents who later developed non-affective psychosis [55]. Both childhood trauma and cannabis use were significantly associated with an increased risk of functional psychosis. Neurotic personality also contributed independently to this risk. These findings might help to improve the prevention of psychosis and aid in the development of specific treatment strategies [36].

Despite the strong genetic association with psychosis, recent studies, including monozygotic twin concordance studies, have found that psychosis is influenced even more by the environment, as the nature of the environment and a person's lifestyle do affect and interact with gene expression. Environmental risk factors can be divided into the following stages: (1) early life risk factors, which include prenatal and perinatal complications; (2) childhood risk factors, which include head injuries and child abuse; and (3) later-life risk factors, which include drug abuse and negative life events associated with trauma [37].

The risk factors of psychosis were divided based on their onset of assessment into (1) baseline risk factors, which could be assessed throughout the life of the individual and include (a) genetic profile, as a person who has a first-degree relative with psychosis has an increased risk for psychosis and psychotic disorders, and (b) the sex of an individual, as males have an increased risk; (2) distal risk factors that are assessed distally to the onset of illness such as (a) abnormal fetal environment and (b) abnormal cognitive development; proximal risk factors that are assessed proximally to the onset of illness and include: (a) prodromal psychotic symptoms, (b) biomarkers such as elevated dopamine levels in the brain and decreased cortical size, which can be assessed using modern neuroimaging techniques [38].

Impairment of social function was significantly associated with early conversion to psychosis in clinically high-risk individuals, and it is considered a risk factor of poor outcomes [4].

The idea that disturbances occurring early in brain development contribute to the pathogenesis of schizophrenia is often referred to as the neurodevelopmental hypothesis. International studies indicate that the prevalence of psychotic experiences in children is 7%. It has been
suggested that environmental stress, socioeconomic status, maternal health conditions, and infections during pregnancy may affect the neurodevelopment of the fetus and lead to a vulnerability in the child to later stressors and psychopathology [39-41].

**Protective factors against psychosis**

It has been speculated that both environmental and genetic factors have synergistic interaction in the initiation of psychosis. This complex interplay provides an insight into the role of a positive environment in protecting genetically susceptible individuals, particularly if these individuals are adolescents, as environmental factors are important at this stage [42-43]. Protective factors against psychosis can be categorized into three main groups: personal, family, and social.

In the study of psychosis, the role of the family environment, apart from the family history of psychosis, has received little attention. The impact of positive remarks and warmth from caregivers improved social functioning and symptoms in patients with psychotic prodrome [44]. Furthermore, there appears to be an adverse relationship between parental warmth and the contribution of genetic factors as the influence of genetic factors drop to almost zero in those that have received higher parental warmth [42].

Interestingly, family planning has also been found to modify an individual’s psychiatric risk. A family of four children and less, with a gap of two years or more, has been found to have a protective effect. External familial support is of great value, and society plays a role. A good parenting system, clear boundaries at home, and a healthy relationship with siblings play a role in protecting against psychosis [45-46].

Attention has long been paid to exploring the role of personality in psychopathology. The five-factor model (FFM) or big five model consists of the following personality traits: neuroticism, extraversion, openness, agreeableness, and conscientiousness. Of all the personality traits, only neuroticism, which is characterized by vulnerability to emotional instability and self-consciousness, was positively associated with psychosis. Whereas the other four traits were considered negatively associated with psychosis and were, in fact, protective. Additionally, qualities like resilience are valuable for protecting against demanding environments [47-48].

A relatively higher intelligence quotient (IQ), higher neighborhood social cohesion, and positive home characteristics were found to be protective against psychosis, even among those exposed to multiple forms of victimization [49].

**Conclusions**

Psychosis is a syndrome that is diagnosed by exclusion after secondary causes are ruled out. It is characterized by a disconnection from reality. Several genetic, environmental, and protective risk factors have been identified and require further study. The WHO considers psychotic disorders as a cause of disability. Psychotic disorders are a significant economic burden. Therefore, it is essential to try to detect the disease in its prodromal stage, where intervention may slow its progression and improve general wellbeing. Several tools have been identified to screen for prodrome, one of which is the PQ-B. This has been shown to be a promising tool that can be self-administered by the patient, in contrast to long interview-based tools, which are time-consuming and require a physician to perform. Despite the limited evidence, significant improvement has been found in the outcomes of patients with psychosis when they were treated in the prodromal period, especially with CBT. More trials should be undertaken to establish generalized guidelines for the treatment of psychosis in the prodromal stage.
Additional Information

Disclosures

Conflicts of interest: In compliance with the ICMJE uniform disclosure form, all authors declare the following: Payment/services info: All authors have declared that no financial support was received from any organization for the submitted work. Financial relationships: All authors have declared that they have no financial relationships at present or within the previous three years with any organizations that might have an interest in the submitted work. Other relationships: All authors have declared that there are no other relationships or activities that could appear to have influenced the submitted work.

References

1. NAMI. Understanding psychosis. (2014). Accessed: April 18, 2020: https://sardaa.org/wp-content/uploads/2015/08/Nami_Understanding_Psychosis_Booklet.pdf.
2. McLaren J, Silins E, Hutchinson D, Mattick R, Hall W: Assessing evidence for a causal link between cannabis and psychosis: a review of cohort studies. Int J Drug Policy. 2010, 21:10-19. 10.1016/j.drugpo.2009.09.001
3. Kohler C, Gur R, Swanson C, Petty R, Gur R: Depression in schizophrenia: association with neuropsychological deficits. Biol Psychiatry. 1998, 45:165-172. 10.1016/S0006-5225(97)00035-4
4. Heckers S: Who is at risk for a psychotic disorder? Schizophr Bull. 2009, 35:847-850. 10.1093/schbul/sbp078
5. Gonçalves A, Dantas C, Banzato C, Oda A: A historical account of schizophrenia proneness categories from DSM-I to DSM-5 (1952-2013) [Article in French]. Revista Latinoamericana de Psicopatologia Fundamental. 2018, 21:798-828. 10.1590/1415-4714.2018v21n4p798.7
6. Shervin M, McElroy E, Christoffersen M: Elklit A, Hyland P, Murphy J: Social, familial and psychological risk factors for psychosis: a birth cohort study using the Danish registry system. Psychiatry. 2016, 8:95-105. 10.1080/17522439.2015.1113306
7. Feinberg M, Button T, Neiderhiser J, Reiss D, Hetherington E: Parenting and adolescent antisocial behavior and depression. Arch Gen Psychiatry. 2007, 64:457-465. 10.1001/archpsyc.64.4.457
8. Loebel A, Lieberman J, Alvir J, Mayerhoff D, Geisler S, Szymanski S: Duration of psychosis and outcome in first-episode schizophrenia. Am J Psychiatry. 1992, 149:1183-1188. 10.1176/ajp.149.9.1183
9. Xu L, Zhang T, Zheng L, et al.: Psychometric properties of prodromal questionnaire-brief version among Chinese help-seeking individuals. PLoS One. 2016, 11:e0148955. 10.1371/journal.pone.0148955
10. Hanssen M, Bijl R, Vollebergh W, van Os J: Self-reported psychotic experiences in the general population: a valid screening tool for DSM-III-R psychotic disorders?. Acta Psychiatr Scand. 2003, 107:369-377. 10.1034/j.1600-0447.2003.0005x
11. Cannon T, Cadenhead K, Cornblatt B, et al.: Prediction of psychosis in youth at high clinical risk. A multisite longitudinal study in North America. Arch Gen Psychiatry. 2008, 65:28. 10.1001/archgenpsychiatry.2007.5
12. Gross G, Huber G, Klosterkötter J, Klosterkötter J, Linz M: Scale for the Assessment of Basic Symptoms (BSABS). Springer Verlag, New York, United States; 1987.
13. Miller T, McGlashan T, Woods S, et al.: Symptom assessment in schizophrenic prodromal states. Psychiatr Q. 1999, 70:275-287. 10.1023/a:1022034115078
14. Loewy RL, Pearson R, Vinogradov S, Bearden CE, Cannon TD: Psychosis risk screening with the prodromal questionnaire — brief version (PQ-B). Schizophr Res. 2011, 129:42-46. 10.1016/j.schres.2011.03.029
15. Yung A, McGorry P: The prodromal phase of first-episode psychosis: past and current conceptualizations. Schizophr Bull. 1996, 22:353-370. 10.1093/schbul/22.2.355
16. Yung A, Yuen H, McGorry P, et al.: Mapping the onset of psychosis: the comprehensive assessment of at-risk mental states. Aust N Z J Psychiatry. 2005, 39:964-971. 10.1080/j.1440-1614.2005.01714.x
18. Halouani N, Feki R, Turki M, Boudabous J, Masmoudi R, Aloulou J, Amami O: First episode psychosis: socio demographic characteristics and prodrome. Eur Psychiatry. 2015, 50:888. 10.1016/S0924-9358(15)30695-3

19. Falloon I: Early intervention for first episodes of schizophrenia: a preliminary exploration . Br J Psychiatry. 1992, 55:4-15. 10.1080/00048674.1992.11024572

20. McGorry P, Yung A, Phillips L, et al.: Randomized controlled trial of interventions designed to reduce the risk of progression to first-episode psychosis in a clinical sample with subthreshold symptoms. Arch Gen Psychiatry. 2002, 59:921. 10.1001/archpsyc.59.10.921

21. Zhang T, Xu L, Tang X, et al.: Real-world effectiveness of antipsychotic treatment in psychosis prevention in a 5-year cohort of 517 individuals at clinical high risk from the SHARP (ShangHai At Risk for Psychosis). Aust N Z J Psychiatry. 2020, [Epub]:10.1177/0004867420917449

22. Addington J, Marshall C, French P: Cognitive behavioral therapy in prodromal psychosis . Curr Pharm Des. 2012, 18:558-565. 10.2174/138161212799516082

23. Almutairi A: Mental illness in Saudi Arabia: an overview . Psychol Res Behav Manag. 2015, 8:47-49. 10.2147/PRBM.S79268

24. Roca M, Gili M, Garcia-Garcia M, Salva J, Vives M: Garcia Campayo J, Comas A: Prevalence and comorbidity of common mental disorders in primary care. J Affect Disord. 2009, 119:52-58. 10.1016/j.jad.2009.03.014

25. Kirkbride J, Stubbs C, Jones P: Psychosis incidence through the prism of early intervention services. Br J Psychiatry. 2012, 200:156-157. 10.1192/bjp.bp.111.094896

26. Kirkbride J, Hameed Y, Ankireddy Palli G, et al.: The epidemiology of first-episode psychosis in early intervention in psychosis services: findings from the Social Epidemiology of Psychoses in East Anglia [SEPEA] study. Am J Psychiatry. 2017, 174:143-153. 10.1176/appi.ajp.2016.16010103

27. WHO. Schizophrenia. (2018). Accessed: April 19, 2020: https://www.who.int/news-room/fact-sheets/detail/schizophrenia.

28. Schizophrenia in adults: clinical manifestations, course, assessment, and diagnosis . (2020). Accessed: April 19, 2020: https://www.uptodate.com/contents/schizophrenia-in-adults-clinical-manifestations-course-assessment-and-diagnosis?sea....

29. Quality of life for people with schizophrenia in Saudi Arabia . (2012). Accessed: April 19, 2020: https://pdfs.semanticscholar.org/2e87/2e28573bcb0081f1f7d967c578550a5cd07da.pdf.

30. Al Fayez H, Lappin J, Murray R, Boydell J: Duration of untreated psychosis and pathway to care in Riyadh, Saudi Arabia. Early Interv Psychiatry. 2015, 11:47-56. 10.1111/eip.12214

31. Fusar-Poli P, Tantardini M, De Simone S, et al.: Deconstructing vulnerability for psychosis: meta-analysis of environmental risk factors for psychosis in subjects at ultra high-risk. Eur Psychiatry. 2016, 40:65-75. 10.1016/j.eurpsy.2016.09.003

32. Zammit S, Lewis G, Dalman C, Allebeck P: Examining interactions between risk factors for psychosis. Br J Psychiatry. 2010, 197:207-211. 10.1192/bjp.bp.109.079094

33. Craddock N, O’Donovan M, Owen M: Psychosis genetics: modeling the relationship between schizophrenia, bipolar disorder, and mixed (or ‘schizoaffective’) psychoses. Schizophr Bull. 2009, 55:482-490. 10.1093/ schbul/ bsp020

34. Bailey T, Alvarez-Jimenez M, Garcia-Sanchez A, Hulbert C, Barlow E, Bendall S: Childhood trauma is associated with severity of hallucinations and delusions in psychotic disorders: a systematic review and meta-analysis. Schizophr Bull. 2018, 44:1111-1122. 10.1093/schbul/sbx161

35. Sormunen E, Saarinen M, Salokangas R, et al.: Effects of childhood and adolescence physical activity patterns on psychosis risk- a general population cohort study. NPJ Schizophrenia. 2017, 3:5. 10.1038/s41557-016-0007-z

36. Barrigón M, Díaz F, Gurpegui M, et al.: Childhood trauma as a risk factor for psychosis: a sib-pair study. J Psychiatr Res. 2015, 70:150-156. 10.1016/j.jpsychires.2015.08.017

37. van Os J, Pedersen C, Mortensen P: Confirmation of synergy between urbanicity and familial liability in the causation of psychosis. Am J Psychiatry. 2004, 161:2312-2314. 10.1176/appi.ajp.161.12.2312

38. Dean K, Murray R: Environmental risk factors for psychosis . Dialogues Clin Neurosci. 2005, 7:69-80.

39. Owen M, O’Donovan M: Schizophrenia and the neurodevelopmental continuum: evidence
from genomics. World Psychiatry. 2017, 16:227-235. 10.1002/wps.20440

40. Blomström Å, Karlsson H, Gardner R, Jörgensen L, Magnusson C, Dalman C: Associations between maternal infection during pregnancy, childhood infections and the risk of subsequent psychotic disorder—a Swedish cohort study of nearly 2 million individuals. Schizophr Bull. 2015, 42:125-133. 10.1093/schbul/sbv112

41. Dorrington S, Zammit S, Asher L, Evans J, Heron J, Lewis G: Perinatal maternal life events and psychotic experiences in children at twelve years in a birth cohort study. Schizophr Res. 2014, 152:158-165. 10.1016/j.schres.2013.11.006

42. Feinberg M, Button T, Neiderhiser J, Reiss D, Hetherington E: Parenting and adolescent antisocial behavior and depression. Arch Gen Psychiatry. 2007, 64:457-465. 10.1001/archpsyc.64.4.457

43. Östman O: Patients in child and adolescent psychiatric care: psychopathology and background factors. Acta Psychiatr Scand. 1989, 80:408-414. 10.1111/j.1600-0447.1989.tb02997.x

44. O'Brien M, Gordon J, Bearden C, Lopez S, Kopelowicz A, Cannon T: Positive family environment predicts improvement in symptoms and social functioning among adolescents at imminent risk for onset of psychosis. Schizophr Res. 2006, 81:269-275. 10.1016/j.schres.2005.10.005

45. Institute of Medicine; Committee on Prevention of Mental Disorder: Reducing Risks for Mental Disorders: Frontiers for Preventive Intervention Research. Patricia J. Mrazek, Robert J. Haggert (ed): National Academy Press, Washington, DC; 1994.

46. Pruessner M, Iyer S, Faridi K, Joober R, Malla A: Stress and protective factors in individuals at ultra-high risk for psychosis, first episode psychosis and healthy controls. Schizophr Res. 2011, 129:29-35. 10.1016/j.schres.2011.05.022

47. Shi J, Yao Y, Zhan C, Mao Z, Yin F, Zhao X: The relationship between big five personality traits and psychotic experience in a large non-clinical youth sample: the mediating role of emotion regulation. Front Psychiatry. 2018, 9,[Epub]. 10.3389/fpsyt.2018.00648

48. Campbell-Sills L, Cohan S, Stein M: Relationship of resilience to personality, coping, and psychiatric symptoms in young adults. Behav Res Ther. 2006, 44:585-599. 10.1016/j.brat.2005.05.001

49. Crush E, Arseneault L, Jaffee S, Danese A, Fisher HL: Protective factors for psychotic symptoms among poly-victimized children. Schizophr Bull. 2017, 44:691-700. 10.1093/schbul/sbx111